MET and non-small cell lung carcinoma: The overall incidence of MET exon 14 skipping mutations in NSCLC is 3% to 4% with untreated NSCLC or previously treated molecularly driven NSCLC, such as EGFR, and acts as a mechanism of acquired resistance.